Current status and perspectives in lung transplantation

P. Vitulo


EDITORIAL

More than two decades after the very first lung transplant was successfully performed by the Toronto Lung Transplant Group, lung transplantation (LTX) has become a valid approach to treatment of end-stage parenchymal and vascular lung disease due to the satisfactory results achieved in terms of survival and quality of life.

According to the Registry of the International Society of Heart and Lung Transplantation, the current 1-, 2- and 5-yr overall actuarial survival following LTX is 77.1%, 61.1% and 47.5% respectively [1]. Long term survival is mainly affected by the onset of obliterative bronchiolitis, an irreversible form of chronic lung rejection. Although the survival rates following LTX are considerably lower than after liver or heart transplantation, LTX still provides a remarkable advantage in terms of quality of life. These encouraging results have widened the indications for LTX, thus resulting in an increased number of patients awaiting an operation.

The indications for LTX seem to have a different distribution according to which country they are in. In the US, for example, Chronic Obstructive Pulmonary Disease accounts for 48% of all the patients listed for LTX, Idiopathic Pulmonary Fibrosis for 17% and Cystic Fibrosis for 16%; in Italy, in contrast, the same indications account for 28%, 23% and 21% of the patients referred for LTX, respectively. This is in part due to different organ allocation policies. In the US, the allocation of lungs is based on the time accrued by each patient on the waiting list; in the majority of European Countries, however, the selection of the recipient is made by the local transplant team. The latter system allows for a disease-oriented selection, and takes into account the severity of each patient’s prognosis and clinical status.

The number of patients on the waiting list seems to increase at a higher rate in the US than in Europe [2]. This could reflect a more careful patient selection in the European centres. Nevertheless, this data needs to be carefully reviewed, since a single candidate could be registered in more than one centre in the US, while this rarely occurs in Europe.

Despite these differences, the majority of lung transplant centres are facing the condition of a substantially stable number of organs available for LTX versus a growing trend of patients listed for transplant. The imbalance between demand and offer is reflected by the worrying increase in the number of patients dying on the waiting list.

Organ shortage implies several ethical, economic and logistic issues and requires the optimisation of the process of recipient selection, organ procurement strategy, and graft preservation, in order to allow a safer use of the so-called “marginal donors”.

The selection process of LTX candidates should take into account the following aspects: stage, natural history and recent evolution of the underlying disease; general functional status of the patient (nutrition, walking capacity); an estimate of the waiting time based on the type of transplant, the ABO and dimensional matching, and the average waiting time in the selected centre.

In the case of pulmonary vascular disease, the prognosis of patients with associated congenital heart disease is generally better than those with idiopathic pulmonary hypertension, despite the fact that in both cases hemodynamic and respiratory parameters are heavily altered.

The paper from G. Callegari and co-workers published in this issue of Monaldi Archives [3] reports the experience of the Pavia Lung Transplant Centre with a large group of patients affected by Eisenmenger Syndrome who were listed for LTX. The authors retrospectively investigated for predictors of survival among clinical, respiratory, and hemodynamic parameters. No significant differences were noted between the group of survivors and those who died. An unfavourable trend was seen in those patients who had heart defects and...
The induction of tolerance to donor-specific antigens seems the more promising road to rejection-free LTX. The administration of depleting or blocking agents and immunomodulatory cell populations could prolong graft function and minimize drug toxicity.

References